# Immunotherapy in Patient With Poor General Condition

> **NCT04108026** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 50 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Stage IV

## Interventions

- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04108026
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-14
- **Primary completion:** 2023-11-30
- **Final completion:** 2025-09-26
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108026, "Immunotherapy in Patient With Poor General Condition". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04108026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*